<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37852270</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-0221</ISSN><JournalIssue CitedMedium="Internet"><Volume>90</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Planta medica</Title><ISOAbbreviation>Planta Med</ISOAbbreviation></Journal><ArticleTitle>Establishment of the Daucus carota SMC-1 Cell Suspension Line for Poliovirus Vaccine Development.</ArticleTitle><Pagination><StartPage>63</StartPage><EndPage>72</EndPage><MedlinePgn>63-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/a-2181-2886</ELocationID><Abstract><AbstractText>The development of virus-free, oral vaccines against poliovirus capable of inducing mucosal protective immunity is needed to safely combat this pathogen. In the present study, a carrot cell line expressing the poliovirus VP2 antigen was established at the level of callus and cell suspensions, exploring the effects of culture media (MS and B5), supplementation with urea, phytoregulators (2,4-D : KIN), and light conditions (continuous light, photoperiod, and total darkness). The best callus growth was obtained on B5 medium supplemented with 2 mg/L of 2,4-D + 2 mg/L kinetin and 0.0136 g/L of urea and in continuous light conditions. Suspension cultures of the SMC-1 line in 250 mL Erlenmeyer flasks had a maximum growth of 16.07 ± 0.03 g/L DW on day 12 with a growth rate of µ=0.3/d and a doubling time of 2.3 days. In a 2 L airlift bioreactor, the biomass yield achieved was 25.6 ± 0.05 g/L DW at day 10 with a growth rate of µ= 0.58/d and doubling time of 1.38 d. Cell growth was 1.5 times higher in bioreactors than in shake flasks, highlighting that both systems resulted in the accumulation of VP2 throughout the time in culture. The maximum VP2 yield in flasks was 387.8 µg/g DW at day 21, while in the reactor it was 550.2 µg/g DW at day 18. In conclusion, bioreactor-based production of the VP2 protein by the SMC-1 suspension cell line offers a higher productivity when compared to flask cultures, offering a key perspective to produce low-cost vaccines against poliomyelitis.</AbstractText><CopyrightInformation>Thieme. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales-Aguilar</LastName><ForeName>Mónica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolaños-Martínez</LastName><ForeName>Omayra Citlalli</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Laboratorio de Biofarmacéuticos Recombinantes, Universidad Autónoma de San Luis Potosí, SLP, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Andrea Romero</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Laboratorio de Biofarmacéuticos Recombinantes, Universidad Autónoma de San Luis Potosí, SLP, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina (CICSaB), Universidad Autónoma de San Luis Potosí, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Govea-Alonso</LastName><ForeName>Dania O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>Laboratorio de Biofarmacéuticos Recombinantes, Universidad Autónoma de San Luis Potosí, SLP, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina (CICSaB), Universidad Autónoma de San Luis Potosí, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carreño-Campos</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villarreal</LastName><ForeName>María Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosales-Mendoza</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratorio de Biofarmacéuticos Recombinantes, Universidad Autónoma de San Luis Potosí, SLP, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina (CICSaB), Universidad Autónoma de San Luis Potosí, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz-Caltempa</LastName><ForeName>Anabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Investigación en Biotecnología, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>848290</GrantID><Agency>Consejo Nacional de Ciencia y Tecnología</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Planta Med</MedlineTA><NlmUniqueID>0066751</NlmUniqueID><ISSNLinking>0032-0943</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>8W8T17847W</RegistryNumber><NameOfSubstance UI="D014508">Urea</NameOfSubstance></Chemical><Chemical><RegistryNumber>2577AQ9262</RegistryNumber><NameOfSubstance UI="D015084">2,4-Dichlorophenoxyacetic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018552" MajorTopicYN="Y">Daucus carota</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="Y">Poliovirus Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014508" MajorTopicYN="N">Urea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015084" MajorTopicYN="N">2,4-Dichlorophenoxyacetic Acid</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>19</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>18</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37852270</ArticleId><ArticleId IdType="doi">10.1055/a-2181-2886</ArticleId></ArticleIdList></PubmedData></PubmedArticle>